BRONCUS-B: Lung imaging processing software BRONCQCT® approved for market launch in China

According to the Zhitong Finance APP, BRONCUS-B (02216) announced that its lung imaging processing software BroncQCT® (hereinafter referred to as "the software") has officially been approved by the Zhejiang Provincial Drug Administration for listing in China. The approval of this software reflects the group's commitment to developing solutions that enhance clinical benefits and further consolidates the company's position in the field of precise intervention diagnosis and treatment of lung diseases. It is expected that this software will improve doctors' efficiency in reading lung computed tomography (CT) images, providing strong support for clinical auxiliary diagnosis and treatment, and promoting a more efficient and accurate diagnostic process.

The software processes CT images through algorithms, performing lung segment segmentation and analysis, achieving quantitative data visualization and three-dimensional reconstruction of lung structures, and providing reading reports for professional doctors, crossing various applications with significant clinical value. This software can be used for efficient large-scale imaging screening in patient populations to identify patients with specific lung characteristics. Additionally, the software supports the analysis of images from the same patient at different times, allowing for objective comparison and monitoring of changes in lung parameters over time, thereby optimizing the efficiency of clinical workflows. Together with the company's interventional treatment products InterVapor® thermal vapor treatment system and BroncAblate® intelligent radiofrequency ablation system, it provides a comprehensive solution for lung disease screening, diagnosis, and treatment, fully safeguarding patients' lung health